China Biologic Products, Inc. ("CBP," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("China" or the "PRC"), today announced that the Company has been approved by the Chinese State Food and Drug Administration (the "SFDA") to commence the production of Human Albumin 12.5g/vial (25%, 50 ml).
Human Albumin 12.5g/vial (25%, 50 ml), contains the highest concentration and delivers the highest dosage of the Human Albumin family products in Mainland China, and has a better effect on the clinical application for ascites due to liver cirrhosis, external injuries, hydrocephalus due to cerebral hemorrhage, serious hypoproteinemia, and other major diseases. With this approval, CBP is now one of the few producers offering the widest range of Human Albumin products available in China.
"We are pleased to receive approval from the SFDA to produce this concentration and dosage of Human Albumin," said Mr. Chaoming Zhao, CFO of China Biologic. "The approval represents a significant milestone for our Company."
The Company has already commenced the production and marketing of this new product.
(Source:www.pharmalive.com)
No comments:
Post a Comment